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Introduction
Seizures have been recognised in the context of mul-
tiple sclerosis (MS) since the earliest reports of the 
disease.1 Although the reported prevalence varies, sei-
zures are more frequent than in the general popula-
tion,2–4 occurring in about 2%–3% of all patients with 
MS.5–8 The origin, extent and importance of this 
increase above the baseline incidence is uncertain. 
Cross-sectional studies show a minimal rise in the 
incidence of seizures,9 whereas retrospective assess-
ment where MS is present for up to 20 years found an 
incidence three times above baseline.3,8 Patients with 
significant disability have a further increase in seizure 
frequency to 4.25%,10 rising to 7% in those requiring 
baclofen.11 The picture is further complicated by the 
fact that some medications prescribed for MS may 
increase the incidence of seizures (e.g. baclofen), 
while other therapies (e.g. carbamazepine) may 
reduce this incidence.
Seizures are a manifestation of excessive and/or hyper-
synchronous activity of neurons in the brain12 and are 
seen in the context of a neuronal insult. MS is classi-
cally considered an inflammatory demyelinating dis-
ease of the white matter (WM). Though the pathological 
substrate of seizures in MS remains to be determined, 
the emerging appreciation of cortical pathological pro-
cesses and neuronal loss in MS13,14 may help to explain 
the observed increased rate of seizures in MS. Magnetic 
resonance imaging (MRI) studies have demonstrated 
new plaques in the juxtacortical and/or cortical regions 
in patients with generalised convulsions15,16 and also 
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higher cortical-subcortical lesion loads in those with 
epilepsy,17 suggesting that a relationship existed 
between the extent of the cortical and subcortical 
lesions and the presence of seizures. Moreover, it has 
been demonstrated that relapsing–remitting MS 
(RRMS) patients with epilepsy have a more severe and 
rapidly evolving cortical pathology compared with 
RRMS without epilepsy.18
Unfortunately MRI provides an incomplete assess-
ment of neuronal processes that may be active around 
the time of onset of epilepsy due to both intrinsic limi-
tations of the technique and because it is performed at 
a time distant from the seizure event. Neuropathology 
does allow us to assess neuronal processes in more 
detail, although as with MRI it is distant from the sei-
zure event. Neuropathological studies have shown 
changes in GABAergic neurotransmission and 
interneuron loss that could increase susceptibility to 
seizures,19,20 and on that basis it has been hypothesised 
that epileptogenic neuronal foci could result from cor-
tical pathology, which might otherwise be relatively 
asymptomatic.10,16,17 The United Kingdom (UK) MS 
Tissue Bank (MSTB) population is unique in that it is 
recruited throughout the UK, with analysis of the neu-
ropathology ultimately being available to confirm the 
diagnosis. Using this population we analysed the prev-
alence of seizures and correlated this with an in-depth 
study of the possible pathological substrate.
Material and methods
Demographic and clinical data
The UK MS Tissue Bank (UKMSTB) has multi-cen-
tre research ethics approval for a national prospective 
donor scheme (MREC/02/2/39). Once a registered 
donor has died, a summary of the clinical history is 
prepared by a clinical neurologist with an interest in 
MS.21,22 Any history of seizures was noted including 
the date of seizure onset and the basis on which a 
diagnosis of seizures was made. Seizures were classi-
fied according to the International League Against 
Epilepsy guidelines.23 Concurrent infection was rele-
vant if a temperature was documented prior to or 
within 24 hours of admission and/or antibiotics were 
being taken prior to or on admission and or concurrent 
infection was documented as a cause of the seizure in 
the clinical notes. Fifty-one individuals with MS (21 
patients with MS and seizures, 30 patients with MS 
alone without seizures (Table 1)) and eight controls 
without evidence of neurological disease or neuro-
pathological alterations were chosen sequentially 
from the UKMSTB based on tissue availability and 
suitability of tissue preservation.
Detailed cortical tissue and lesion classification
Paraffin-embedded tissue blocks from precentral, 
superior frontal and middle temporal gyri were 
examined. In the patients with MS the degree of 
inflammation, the extent of demyelination and 
degree of lesion activity were evaluated as previ-
ously described.20,24 Grey matter lesions (GMLs) 
were characterised into Type I (grey matter (GM)/
WM junction) or Type III (subpial), according to the 
criteria of Peterson et al.25
Immunohistochemistry
From each formaldehyde-fixed, paraffin-embedded 
tissue block, 5-µm-thick paraffin sections were pro-
cessed and immunostained as previously described.20 
All sections were counterstained with haematoxylin, 
sealed and viewed with a Nikon E1000M microscope. 
Images were captured (QImaging) and analysed using 
Image Pro Plus software (Media Cybernetics).
Quantitative analysis of demyelinated lesions, 
cortical atrophy and neuronal density
For each tissue block one section was stained for 
luxol fast blue (LFB)/cresyl fast violet (CFV) and one 
was immunostained for myelin oligodendrocyte gly-
coprotein (MOG) and detailed evaluation of WM and 
GM demyelination and cortical thickness was per-
formed as previously described.20 Cortical thickness 
was evaluated on paraffin sections from precentral 
gyrus, superior frontal gyrus and middle temporal 
gyrus. To obtain a detailed analysis of the neuronal 
pathology in the GM, quantification of the numerical 
density of the NeuN+ and GAD67+ cells was per-
formed on serial paraffin sections from the middle 
temporal and superior frontal gyrus of six MS cases 
with seizures (a in Table 1, five of whom had seizures 
associated with concurrent infection) and six MS 
cases without seizures, compared to the GM of six 
controls. All cases were randomly chosen and ana-
lysed blinded to case identification. To determine 
mitochondrial respiratory chain complex IV 
(cytochrome-c oxidase (COX)) and complex II (suc-
cinate dehydrogenase (SDH)) activity, COX and SDH 
histochemistry was performed in serial sections and 
in single cells as previously described.26
Statistical analysis
Clinical data were analysed using nonparametric tests 
for the role of concurrent infection. Statistical analy-
sis of the histological data was performed using one-
way analysis of variance (ANOVA) and Bonferroni’s 
multiple comparison tests.
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Table 1. Epilepsy in patients with MS.
ID Seizure 
onset 
(years)
Seizure history, treatment 
(diagnosed by),
secondary to concurrent 
infection, type of infection
Investigations: EEG (date) Age of 
MS onset 
(years)
Age 
wheelchair 
user (years)
Age died 
(years)
Onset after first symptoms of MS
MS020 35 Blackout (neurologist), no ‘Moderate bilateral 
disturbances, paroxysmal 
with left temporal emphasis’
23 38 60,
MS022 54 Tonic clonic (neurologist), no – 39 49 56
MS029 56 Tonic clonic (A+E, neurologist), 
yes, UTI
– 29 43 59
MS037 62 Blackout, incontinent, confused 
on recovery, anticonvulsants 
(neurologist), yes, UTI
‘Diffusely abnormal, more 
than would be expected in 
MS’
30 54 76
MS038 40 Tonic clonic, carbamezepine 
(neurologist), yes, UTIs
– 24 27 42
MS040 54 Right-sided focal (neurologist), 
yes, chest infection
– 36 46 58
MS049 55 Tonic clonic, (ITU), no ‘Right temporal slow waves’ 
(1965)
37 76 76
MS053 59 Tonic clonic (neurologist), no – 31 53 66
MS074* 63 Tonic clonic (neurologist), yes, 
chest infection
– 28 50 64
MS076 42 Definite generalised seizures, 
phenytoin (neurologist), No
‘Abnormal’ (1983 – at time 
of diagnosis of MS when had 
paroxysmal movements – not 
seizures)
31 45 49
MS079* 49 Temporal: complex partial, left-
sided onset (neurologist), yes, 
chest infection – cause of death
– 25 35 49
MS092 26 Tonic clonic (neurologist), no – 21 28 38
MS104a 50 Tonic clonic, carbamezepine 
(neurologist), yes, UTIs
– 41 46 53
MS112a 57 Tonic clonic (A+E), yes, UTIs – 30 35 66
MS124 28 Right-sided focal (neurologist), 
no
– 25 26 30
MS127 51 Tonic clonic (neurologist), yes, 
abscess buttock
– 28 47 52
MS131 51 Temporal: partial (neurologist), 
no
– 31 44 56
MS135 59 Temporal: left-sided focal with 
loss of awareness (neurologist), 
no
– 24 43 61
MS142 62 Right-sided with secondary 
generalisation (neurologist), yes, 
UTI
– 35 61 67
MS147 57 Right-sided with secondary 
generalisation (neurologist), no
– 38 52 60
MS161 62 Tonic clonic, carbamezepine 
(neurologist), yes, UTI
– 42 - 69
MS172 53 Tonic clonic (neurologist), no – 26 46 58
MS186 47 Tonic clonic with infections, 
carbamezepine (neurologist), 
yes, chest infection
– 20 33 57
(Continued)
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Results
The frequency of seizures is increased in MS in 
the UKMSTB population
Of 255 individuals with MS from the UKMSTB 
cohort, 227 (89%) had secondary progressive MS 
(SPMS), 23 had primary progressive (PPMS) (9%) 
and five had RRMS (2%). Mean age at MS onset 
was 32.6±10.5 years (mean±SD, range 9–66 years), 
240 (94.1%) required a wheelchair with a mean age 
of wheelchair use being 48.6±12.8 years (range 
18–85 years) and a mean age of death 62.0±12.8 
years (range 30–92 years). In the 255 individuals 
and 15,815 person-years of observation, 37 patients 
developed epilepsy, giving a 14.5% lifetime inci-
dence (Table 1).
Seizures in MS are commonly transient and 
associated with concurrent infection
Three patients developed seizures before first symp-
toms of MS; in those, clinical assessment at diagnosis 
confirmed retrospectively, supported a clinical diag-
nosis of primary generalised epilepsy, confirmed in 
one on electroencephalogram (EEG). EEGs were 
available for six of 34 remaining patients of which 
four were abnormal. The diagnosis was made clini-
cally by a neurologist in 94% (32/34 patients). Eight 
ID Seizure 
onset 
(years)
Seizure history, treatment 
(diagnosed by),
secondary to concurrent 
infection, type of infection
Investigations: EEG (date) Age of 
MS onset 
(years)
Age 
wheelchair 
user (years)
Age died 
(years)
MS188 62 Generalised, loss of awareness 
(neurologist), no
– 35 37 78
MS197a 26 Simple (neurologist), no – 24 46 51
MS222 62 Abdominal spasm, phenytoin and 
phenobarbitone (neurologist), no
‘normal’ 31 40 70
MS223 45 Tonic clonic (neurologist), Yes, 
sepsis non-CNS, LP normal
‘normal’ 43 45 45
MS234a 38 Tonic clonic (neurologist), yes, 
UTI
– 23 31 39
MS242 49 Tonic clonic × 2, no treatment 
(neurologist), no
– 38 46 57
MS249 66 Tonic clonic × 2, phenytoin 
(neurologist), yes, UTI
– 27 60 69
MS268 49 Tonic clonic, carbamezepine 
(neurologist), no
– 46 53 54
MS272 45 Nocturnal tonic clonic, valproate 
and lamotrigine (neurologist), no
– 26 44 64
MS278 23 Tonic clonic, no treatment 
(neurologist), no
– 9 23 30
MS298 71 Tonic clonic with infection × 1, 
no treatment (neurologist), yes. 
sepsis secondary to UTI
– 29 68 72
Onset before first symptoms of MS
MS058 7 3 tonic clonic seizures over 18 
months (paediatrician), no
– 31 48 52
MS184 34 Blackouts, (neurologist), no Primary generalised EEG 
abnormality
35 56 74
MS219 13 Generalised, stopped in late teens 
(paediatrician), no
– 40 48 57
MS: multiple sclerosis; ID: identification; EEG: electroencephalogram; CNS: central nervous system; ITU: intensive therapy unit; A+E: accident and emergen-
cy; UTI: urinary tract infection. aIndicates analysed as part of neuronal density analysis.
Table 1. (Continued)
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individuals had focal onset whilst the remainder had 
features supporting secondary generalisation. There 
was no difference in clinical milestones in those with 
focal or generalised seizures.
Notably seizures were associated with immediate 
prior or simultaneous infection in 16/34 (47%) 
patients who developed seizures after MS onset and 
in none of those who had seizures prior to MS onset. 
Concurrent infections were urinary tract infection 
(UTI) in 10, of which one resulted in sepsis, and chest 
infections in four, of which one led to death. In addi-
tion there was one case of a buttock abscess and one 
sepsis with an unknown source but a cerebrospinal 
fluid examination was normal. In those with concur-
rent infection seizures occurred at a significantly 
younger age (42.3±16.5 years) compared with those 
who did not have concurrent infection (54.6±9.5, p < 
0.026, Wilcox test); there was no difference otherwise 
in age of MS onset, age of reaching Expanded 
Disability Status Scale (EDSS) score of 7.0 and death.
Earlier wheelchair use and death occur in those 
with seizures and MS though seizures occurred 
predominantly in the latter phase of MS
The mean age of death was significantly earlier in 
those with seizures (57.6 vs 62.8, t-test, p < 0.022). 
Age of death was also earlier in a Kaplan-Meier anal-
ysis (Figure 1(a)). The presence of seizures was asso-
ciated with earlier wheelchair use (44.7 vs 49.3, t-test, 
p < 0.03), confirmed on Kaplan-Meier analysis (log 
rank test, p < 0.03). However, there was no difference 
in the age of MS onset between those with and with-
out seizures. After 10 years of MS, nine developed 
seizures (24%), and after 15 years 15 developed sei-
zures (41%), the majority developing seizures after 15 
years of disease. Plotting the frequency of seizures as 
related to the proportion of each person’s disease 
(time from age at MS onset to seizure onset/time from 
age at MS onset to age died) (Figure 1(b)), confirmed 
the majority of seizures occur in the latter 20% of the 
disease course. Plotting the frequency of seizures as it 
related to the proportion of each patient’s time to 
require a wheelchair (time from age at MS onset to 
seizure onset/time from MS onset to age at wheel-
chair use) demonstrated that the majority of seizures 
occurred after individuals became wheelchair users 
(Figure 1(c)).
Seizures in patients with MS are associated with 
reduced thickness of the temporal cortex
To examine the neuropathological basis of seizures in 
MS, three separate cortical gyri: precentral, middle 
temporal and superior frontal, were studied. We com-
pared individuals with MS and seizures (n = 21) to 
MS without seizures (n = 30) and controls (n = 8). 
Cortical thickness was reduced in all three gyri in all 
MS groups compared to controls but compared to 
patients with MS alone there was a significant reduc-
tion in cortical thickness in patients with MS and sei-
zures in the middle temporal gyrus (Figure 2).
Seizures in patients with MS are associated with 
Type 1 GMLs in the temporal cortex
In MS patients with seizures GMLs were always pre-
sent in the middle temporal gyrus (21/21), signifi-
cantly above those with MS alone (23/30, p < 0.032). 
GMLs were not always present in either the precen-
tral or superior frontal gyrus nor were there any dif-
ferences in the frequency of GMLs between those 
with and without seizures. Furthermore the increase 
in GMLs in the middle temporal gyrus was in Type I 
GMLs (14/21 with MS and seizures, nine of 30 with 
MS alone, p < 0.01) whereas there was no difference 
in the frequency of Type III GMLs (Table 2).
Selective cortical layer IV and VI interneuron 
loss occurs in the temporal cortex in those with 
seizures and MS
A significant reduction in total NeuN+ neuronal num-
bers was detected in those patients with MS (mean 
19%) compared to controls. In particular, there was 
selective neuronal loss in layers IV (37% vs controls) 
and VI (48% vs controls) of the middle temporal 
gyrus in patients with seizures and MS compared to 
individuals with MS and no seizures. GAD67+ 
interneuron (Figure 3) cell loss mirrored the neuronal 
cell loss observed in layers IV and VI in the middle 
temporal gyrus (Figure 4(b), (d)). No significant dif-
ferences in neuronal density were found in the supe-
rior frontal gyrus (Figure 4(a), (c)).
Selective cortical layer IV and VI interneuron loss 
in the temporal cortex is related to the presence of 
Type 1 GMLs
Histologically, Type I GMLs in the temporal lobe 
were significantly more numerous (14/21 vs 9/30, p < 
0.01) in MS with seizures than those without (Figure 
5(a), (b), Table 2). To determine whether local under-
lying Type I GMLs within the middle temporal gyrus 
were associated with the loss of GAD67+ interneu-
rons, neuronal counts were performed in six controls, 
six patients with MS and seizures and six individuals 
with MS alone in layers IV (Figure 5(c)) and VI 
(Figure 5(d)). Counts were performed in the middle 
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Figure 2. Individuals with MS and seizures (n = 21) were 
compared to controls (n = 8) and MS alone (n = 30). There 
were significant reductions in cortical thickness of all gyri 
in patients with MS compared to controls (mean ± SE).
*p < 0.0015). Compared to patients with MS alone there was a 
significant reduction in cortical thickness in individuals with MS and 
seizures in the middle temporal gyrus (Δp < 0.00003).
Figure 1. Kaplan-Meier survival analysis showed a significantly reduced survival in those with seizures compared to 
those without ((a), log rank test, *p < 0.01). In (b) seizure onset was quantified for each seizure case as a proportion of 
when seizures started from disease onset/total disease length (disease onset to death). This demonstrates that the majority 
of cases occurred in the latter half of their disease. In (c) seizure onset has been quantified from the time from wheelchair 
use to seizure onset/time from wheelchair use to death. Thus a negative × axis score indicates seizures occurred before 
wheelchair use started. This illustrates that the majority of seizures occurred after wheelchair use.
temporal gyrus directly overlying a Type I GML and 
where there was no Type I GML. The interneuron cell 
loss was significantly increased by 43.4% in layer IV 
(Figure 5(c)) and 54.3% in layer VI, where there was 
an underlying lesion compared to where there was no 
lesion (Figure 5(d)).
The presence of inflammatory cells or 
mitochondrial chain activity changes do not 
explain the interneuron cell loss in layers IV and VI
There was no correlation between the degree of neu-
ronal loss in cortical layers IV and VI and the density of 
major histocompatibility complex (MHC) class II+-
activated microglia and/or CD3+ T lymphocytes 
present within the GML in the temporal cortex. 
Mitochondrial respiratory chain complex II and com-
plex IV activity was reduced in a proportion of neurons 
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in Type I GMLs. Both complex II and complex IV 
activity within NeuN+ cells were significantly reduced 
in cortical layer VI of Type I GMLs (n = 6) compared 
with cortical layer VI neurons from controls (n = 6), but 
there was no difference in those with MS with or with-
out seizures (Table 3).
Discussion
This work has shown that seizures are significantly 
increased in MS over the lifespan of the disease in a 
population-based cohort. We confirm that seizures 
increase as the disease progresses, implying seizures 
are the direct result of the neurodegenerative disease 
process. Supporting this we show that seizures are 
associated with earlier use of a wheelchair and an ear-
lier death, but not with early disease onset or early 
high disease activity.27 The unique advantage of this 
study is that it has allowed us to show Type I GMLs 
underlie a local loss of interneurons in cortical layers 
IV and VI in the temporal lobe in association with 
seizures. There are some limitations in this study. 
Firstly we studied only three areas of the brain; this 
does give us a view of the cortex but is not exhaustive. 
Secondly we were able to study in detail only six 
patients with MS and seizures, though five did have 
seizures associated with concurrent infection.
All population-based cohorts have some bias but can 
still offer valuable insights.28 The UKMSTB popula-
tion potentially is biased towards more severe disease 
as there is a younger mean age of death compared to 
other populations.29,30 However, the frequency of 
PPMS is within the range seen in other populations,28 
and the high rates of SPMS result from its unique per-
spective: a diagnosis made at the end of the disease. 
Table 2. GML numbers in the precentral, superiori frontal and middle temporal cortex subdivided into Type I and Type 
III lesions in MS patients with seizures (n = 21) and with MS alone (n = 30).
n Precentral Superior frontal Middle temporal
gyrus gyrus gyrus
GMLs of all types present in each patient (%)
MS 30 22 (73) 26 (87) 23 (77)
MS + seizures 21 11 (52) 16 (76) 21 (100)a
Type I GMLs present in each patient
MS 30 11 12 9
MS + seizures 21 5 6 14b
Type III GMLs present in each patient
MS 30 21 13 13
MS + seizures 21 7 9 8
Lesions were seen in the middle temporal gyrus in 100% of those with MS and seizures, a significant increase above those with MS 
alone (Fisher’s test, ap < 0.032). A significant increase in Type I GMLs but not Type III GMLs in the middle temporal gyrus was seen 
in those with seizures compared to those with MS alone (bFisher’s test, p < 0.01) whereas there was no difference in the frequency of 
Type III GMLs. GML: grey matter lesion; MS: multiple sclerosis.
Figure 3. Neuronal distribution in middle temporal cortex. 
NeuN (column (a)) and GAD67 (column (b)) antibodies 
were used to localise respectively total neurons and 
interneurons in the temporal and cortex. Quantification of 
the numerical density of the NeuN+ nuclei and GAD67+ 
cells is shown in Figure 4. High magnification of GAD67 
immunostaining illustrates the variability in size and shape 
of the interneuron population in the different cortical layers 
(column (b)). Original magnification: 100× = column (a), 
200× = column (b). GM: grey matter.
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Figure 4. Neuronal cell counts ((a), (c)) and GAD-67+ interneuron cell counts ((b), (d)) were performed in six patients with 
MS and seizures and six individuals with MS alone in each layer of the precentral ((a), (b)) and middle temporal gyrus ((c), 
(d)) and compared to six control cases. All cases were randomly chosen and analysed blinded to case identification. The 
percentage of reduction in counts compared to controls is shown (mean ± SE). There is a significant (*p < 0.001) reduction 
in the numbers of neurons and interneurons in layers IV and VI of the middle temporal gyrus. MS: multiple sclerosis.
Figure 5. Demyelination in the temporal grey matter (GM) and white matter (WM) of seizure-positive (a) and seizure-
negative (b) cases. Immunostaining for the myelin oligodendrocyte protein, MOG, shows a Type I GML (in the 
rectangle), in a seizure-positive multiple sclerosis (MS) patient (MS234). Conversely, only a circumscribed WM lesion 
(arrow in (b)) is shown in a seizure-negative patient (MS46). Original magnification: (a), (b) (tiled images) = 100×. 
Interneuron cell counts were performed in patients with MS with and without seizures as well as in controls in layers IV 
(c) and VI (d) to assess the effect of a localised Type I GML. Cell counts (mean ± SE) revealed that the interneuron cell 
loss was significantly (*p < 0.001) reduced in layers IV and VI only local to a Type I GML.
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Table 3. Complex II and IV activity in Neu+ cells within layer VI of the grey matter within lesions, in normal-appearing 
grey matter (NAGM) and in controls.
n Mitochondrial activity in layer VI (mean ± SD)
Complex II
Type I GML 28 4.16±7.36a
NAGM 29 8.35± 4.97
Controls 20 8.26±6.29
Complex IV
Type I GML 42 1.77±7.77b
NAGM 53 5.33±4.01
Controls 44 7.44±5.60
There was a significant reduction in complex II (ap = 0.03) and complex IV (bp = 0.001) activity within the Type I GML only. GML: 
grey matter lesion.
Here we have confirmed that the risk of seizures in 
MS is significantly raised,3,8 not only by showing an 
increased percentage but also through identifying the 
clinical context of that risk. People with MS who had 
seizures at any time during their disease took less time 
from disease onset to require a wheelchair and died 
earlier, although seizures were predominantly associ-
ated with concurrent infection. This confirms that sei-
zure risk increases with more aggressive disease as 
previously implied.10,11
The fact that seizures occur when cortical damage 
and neuronal loss is more severe and after a wheel-
chair is required when the disease is progressive sup-
ports a neurodegenerative process underlying 
seizures. Further support arises from the finding that 
seizures are not associated with predictors of early 
inflammatory activity. Given that seizures arise from 
neuronal dysfunction/damage and are increased in 
the context of cortical damage in neurodegenerative 
diseases such as Alzheimer’s,31 this finding makes 
sense. However, it is not clear whether frequency of 
seizures or poor seizure control is associated with 
more severe disease.
Here we have shown for the first time that in those MS 
cases in which seizures occur there is localised cortical 
damage within the middle temporal gyrus that could 
be a result of loss of interneurons in cortical layers IV 
and VI. This raises two questions: What pathology 
could underlie this and how could it contribute to sei-
zure generation? Type I GMLs extending from the 
WM appear to underlie the temporal lobe damage in 
those with seizures. Although this may produce gen-
eral effects on cerebral function, we have shown that it 
is localised to the area above the lesion itself. The find-
ings are consistent with MRI studies in which Type I 
GMLs were associated with seizures in early MS.10,11 
It appears that this anatomical localisation is important 
as Type III GMLs in the precentral gyrus are associ-
ated with a different pattern of cortical layer damage 
and are not associated with seizures.20 Layer VI cell 
loss could be as a result of damage from inflammatory 
cells ‘spilling’ into the GM from their focus in the 
underlying WM. However, layer IV cell loss was not 
associated with the presence of any infiltrating inflam-
matory cells. The pathology in layers IV and VI may 
arise from damage to the axons of neurons that project 
through the damaged WM of the Type I lesions to 
form synapses on interneurons. Loss of GABAergic 
inhibitory interneuron input from layer IV to excita-
tory pyramidal neurons in layer V in particular will 
lead to excessive excitatory output increasing suscep-
tibility to abnormal electrical activity and to seizures.32 
We cannot, however, exclude a role for seizures them-
selves causing the loss of interneurons.
The origin of seizures in MS could have a variety of 
causes arising from the anatomy of the cell injury and/
or the pathology underlying the injury. We did not 
find any evidence of specific mitochondrial dysfunc-
tion in patients with MS and epilepsy despite the 
known involvement of mitochondria in MS and sei-
zures,19,26 but we did see mitochondrial dysfunction 
within Type I GMLs in cortical layer VI. Mitochondrial 
dysfunction is associated with neuronal excitability 
and glutaminergic activity that could potentially sup-
port the generation of seizures.33 Together with the 
GABAergic interneuron cell loss in layer VI in the 
middle temporal gyrus, dysfunction of surviving neu-
rons in layer VI due to an energy deficit may play an 
important role in the pathogenesis of focal-onset sei-
zures in MS patients.
What is notable here is that 47% of seizures in MS 
were associated with concurrent infections but not 
primary central nervous system (CNS) infections. 
This could be due to infection itself or the associated 
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Figure 6. A proposed mechanism of seizure generation 
in the temporal lobe of patients with MS. A Type I GML 
together with the associated underlying white matter 
lesion, evidenced by and in part due to the presence 
of activated microglia, produce neuronal dysfunction 
(mitochondrial stress) and cell death (interneuron loss 
within layer VI). Resulting damage to projecting neurons 
contributes to the loss of interneurons in layer IV. The 
resulting loss of inhibition enhances the risk of seizures. 
Additional stressors including concurrent infection are 
then more likely to result in the emergence of seizures. 
MS: multiple sclerosis; GML: grey matter lesion.
fever. Peripheral infection drives central inflamma-
tion and could potentially facilitate seizures.34 
However, febrile seizures are well described in chil-
dren where they appear, as here, to be based on abnor-
malities in GABAergic transmission.35 Previous study 
of MS cortex has found a decrease in presynaptic and 
postsynaptic components of GABAergic neurotrans-
mission and in the density of inhibitory interneuron 
processes in MS cortex,19 suggesting that changes in 
the excitatory/inhibitory balance in the GM could 
have an important role in seizure induction. Here we 
have shown these changes in patients with seizures 
are particularly focused in particular layers in the 
temporal cortex, and these changes could increase 
susceptibility to seizures in the context of concurrent 
infection (Figure 6).
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